Report #2873899

Received Nov 20, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: Age unknown
State: NJ
Recovered: Unknown
Vaccinated: Nov 14, 2025
Onset: Nov 14, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	—	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Longer than recommended intervals; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 51-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (first dose was received on 15-DEC-2024). On 14-NOV-2025, the patient received the 2nd dose of Shingrix. On 14-NOV-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Longer than recommended intervals). Additional Information: GSK Receipt Date: 18-NOV-2025 The batch number was not provided and a request for this information has been made.